I-Mab Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- I-Mab Biopharma's estimated annual revenue is currently $30.4M per year.
- I-Mab Biopharma's estimated revenue per employee is $155,000
Employee Data
- I-Mab Biopharma has 196 Employees.
- I-Mab Biopharma grew their employee count by 1% last year.
I-Mab Biopharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder and Chairman | Reveal Email/Phone |
2 | US Site Head, VP | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | VP, Head Global Corporate Alliance | Reveal Email/Phone |
5 | SVP, U.S. & E.U. Business Development | Reveal Email/Phone |
6 | SVP, Operations | Reveal Email/Phone |
7 | Board Secretary; VP Strategy and Planning | Reveal Email/Phone |
8 | Senior Director, Global Medical Safety | Reveal Email/Phone |
9 | Director operations and Global Alliance Management | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
I-Mab Biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is I-Mab Biopharma?
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hong Kong and Maryland, United States.
keywords:N/A
N/A
Total Funding
196
Number of Employees
$30.4M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
I-Mab Biopharma News
Shanghai-based I-Mab is in talks with global drugmakers about a ... market for biopharma IPOs has deteriorated greatly over the past year.
Pre-Open Stock Movers 04/20: AlloVir, I-Mab Biopharma Gain; Netflix Plunges (more...) April 20, 2022 9:23 AM. Pre-Open Stock Movers: Netflix (NASDAQ: NFLX)...
SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical...
Other Companies in Shanghai
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $46.5M | 206 | -1% | N/A |
#2 | $41.6M | 207 | -5% | N/A |
#3 | $32.6M | 212 | -1% | N/A |
#4 | $39.6M | 218 | -9% | N/A |
#5 | $18.8M | 219 | -38% | $151.1M |